Abstract
Diagnosis of type 2 diabetes and prediabetes is mandatory. Chronic hyperglycemia in diabetes is associated with long-term micro- and macrovascular as well as with neurological complications. Prediabetes predisposes patients to develop diabetes and macrovascular disease.
Diagnosis of diabetes is established on (at least) one of the following criteria: a fasting plasma glucose ≥ 126 mg/dl (7.0 mmol/l), a casual plasma glucose ≥ 200 mg/dl (11.1 mmol/l) in the presence of symptoms, a 2-h plasma glucose during the 75-g oral glucose tolerance test (OGTT) ≥ 200 mg/dl (11.1 mmol/l) and/or an HbA1c ≥ 6.5%.
Prediabetes is defined by the Position Statement of the American Diabetes Association as a fasting plasma glucose between 100 and 125 mg/dl (5.6 - 6.9 mmol/l) [a condition called Impaired Fasting Glucose] and/or by a 2-h plasma glucose during OGTT 140 - 199 mg/dl (7.8 - 11.0 mmol) [Impaired Glucose Tolerance] and/or a HbA1c level 5.7 - 6.4%, with however some potential discordance between tests.
The threshold of fasting plasma glucose defining Impaired Fasting Glucose as well as the adequacy of HbA1c as a correct diagnostic tool for prediabetes is still debated.
Keywords: Complications, controversies, definitions, diabetes, prediabetes.
Current Diabetes Reviews
Title:Definitions (and Current Controversies) of Diabetes and Prediabetes
Volume: 12 Issue: 1
Author(s): Martin Buysschaert, Jose-Luis Medina, Benoit Buysschaert and Michael Bergman
Affiliation:
Keywords: Complications, controversies, definitions, diabetes, prediabetes.
Abstract: Diagnosis of type 2 diabetes and prediabetes is mandatory. Chronic hyperglycemia in diabetes is associated with long-term micro- and macrovascular as well as with neurological complications. Prediabetes predisposes patients to develop diabetes and macrovascular disease.
Diagnosis of diabetes is established on (at least) one of the following criteria: a fasting plasma glucose ≥ 126 mg/dl (7.0 mmol/l), a casual plasma glucose ≥ 200 mg/dl (11.1 mmol/l) in the presence of symptoms, a 2-h plasma glucose during the 75-g oral glucose tolerance test (OGTT) ≥ 200 mg/dl (11.1 mmol/l) and/or an HbA1c ≥ 6.5%.
Prediabetes is defined by the Position Statement of the American Diabetes Association as a fasting plasma glucose between 100 and 125 mg/dl (5.6 - 6.9 mmol/l) [a condition called Impaired Fasting Glucose] and/or by a 2-h plasma glucose during OGTT 140 - 199 mg/dl (7.8 - 11.0 mmol) [Impaired Glucose Tolerance] and/or a HbA1c level 5.7 - 6.4%, with however some potential discordance between tests.
The threshold of fasting plasma glucose defining Impaired Fasting Glucose as well as the adequacy of HbA1c as a correct diagnostic tool for prediabetes is still debated.
Export Options
About this article
Cite this article as:
Buysschaert Martin, Medina Jose-Luis, Buysschaert Benoit and Bergman Michael, Definitions (and Current Controversies) of Diabetes and Prediabetes, Current Diabetes Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573399811666150122150233
DOI https://dx.doi.org/10.2174/1573399811666150122150233 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidemiology of Severe Sepsis Around the World
Endocrine, Metabolic & Immune Disorders - Drug Targets A Systematic Review on Synthetic Drugs and Phytopharmaceuticals Used to Manage Diabetes
Current Diabetes Reviews Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Human Pluripotent Stem Cells for Modelling Human Liver Diseases and Cell Therapy
Current Gene Therapy The Application of Prodrug-based Drug Delivery Strategy in Anticancer Drugs
Current Topics in Medicinal Chemistry GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design Aminoglycoside Mimetics as Small-Molecule Drugs Targeting RNA
Current Medicinal Chemistry Synthesis and Clinical Development of Palbociclib: An Overview
Medicinal Chemistry New Insight into 2-Methoxyestradiol- a Possible Physiological Link between Neurodegeneration and Cancer Cell Death
Current Medicinal Chemistry Hsp27 as a Therapeutic Target in Cancers
Current Drug Targets Computer-Aided Drug Design of Bioactive Natural Products
Current Topics in Medicinal Chemistry Editorial [Hot topic: Current Topics on Hypolipidaemic Therapy and Cardiovascular Risk Assessment (Guest Editors: Evangelos C. Rizos and Moses S. Elisaf)]
Current Vascular Pharmacology Effect of Radio Frequency Waves of Electromagnetic Field on the Tubulin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Glucagon and Cyclic AMP: Time to Turn the Page?
Current Diabetes Reviews Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology Protein Cysteine Modifications: (1) Medicinal Chemistry for Proteomics
Current Medicinal Chemistry Nightmares and the Cannabinoids
Current Neuropharmacology Targets and Tools: Recent Advances in the Development of Anti-HCV Nucleic Acids
Infectious Disorders - Drug Targets Preface (Proceedings of the VII Immunonutrition Workshop “Eating for Preventing” [Carovigno, (Italy) May 1-3, 2014] – First Part-)
Endocrine, Metabolic & Immune Disorders - Drug Targets